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CASE REPORT
INTRODUCTION
Amyloidosis is not a single disease but a term for
diseases that share a common feature: the extra
cellular deposition of pathologic insoluble fibrillar
proteins in organs and tissues.1,2,3,4 In the mid-19th
century, Virchow adopted the botanical term “amyloid,”
meaning starch or cellulose, to describe abnormal
extra cellular material seen in the liver at autopsy.1,2,3
The amyloidosis are classified according to
the identity of the fibril-forming protein. Systemic
amyloidoses are neoplastic, inflammatory, genetic, or
iatrogenic in origin, while localized amyloidosis or
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ABSTRACT
Amyloidosis is not a single disease but a term for diseases that share a common feature:
the extracellular deposition of pathologic insoluble fibrillar proteins in organs and tissues. In both
primary and secondary amyloidosis, the most commonly involved organ system is the gastrointestinal
system, with the colon being the most frequently involved organ.
A 30 years-old male, complained of diarrhea since 4 months prior to admission. The colonoscopy
examination revealed pancolitis, ileitis, and the result from histopathological examination showed chronic
destructive ileocolitis with 40-70% amyloidosis of mucosa.
The abdominal ultrasonography showed chronic cholecystitis, multiple cholelithiasis and minimally
ascites. The esophagogastroduodenoscopy revealed candida esophagitis, erosive pangastritis grade V,
pyloring gapping, erosive duodenitis, bile reflux gastritis and esophagitis, and the result from histo-
pathological examination showed amyloidosis on gastric mucosa.The immunofixation electrophoresis was
negative for monoclonal light chains, and the serum protein electrophoresis showed normal pattern.
Enteral and parenteral nutritional therapy were given. Secondary infection was treated by antibiotics.
Complication and organ failure occured lately. This chalenging case demonstrated complicated
management of gastrointestinal  amyloidosis
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organ-limited amyloidoses are associated with aging
and diabetes and occur in isolated organs without
evidence of systemic involvement.2
The two major types of systemic amyloidosis are
AL (primary amyloidosis or myeloma-associated
amyloidosis) and AA (secondary or reactive amyloid).
The former is due to deposition of N-terminus
fragments of immunoglobulin kappa or lambda light
chains, and the latter is associated with the acute phase
reactant Serum Amyloid A (SAA) as the precursor of
the amyloidogenic protein.3
Systemic amyloidosis is generally progressive and
fatal, however the natural history remains poorly
understood, partly due to the lack of clinical
recognition until the process is advanced. Amyloidosis
is not restricted to any age or gender group. Clinical
presentation depends on the distribution and the amount
of amyloid deposited, but symptoms may be protean
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and generally nonspecific. Well-known signs and
symptoms of systemic involvement include
macroglossia, nephrotic syndrome, renal failure,
carpal tunnel syndrome, sensory motor or autonomic
neuropathy, cardiac failure or arrhythmia, hepato-
splenomegaly, diarrhea, malabsorption, ulcerations,
lymphadenopathy, clotting factor deficiencies, capillary
fragility, and abnormalities of platelet aggregation.3
The reported incidence of systemic AL
amyloidosis is one case/100,000 person years in
Western countries. Renal dialysis-related amyloid and
amyloid in brain tissue, which is related to
the 12 million patients with Alzheimer’s disease, are
worldwide. On the contrary, AA amyloidosis, related
to familial Mediterranean fever, is associated with
certain ethnic groups: Sephardic Jews (37%) and
Armenians living in Armenia (24%), and less frequently
in Ashkenazi Jews, Turks, and Arabs (8% to 12%).
AA amyloidosis reportedly affects 17% of patients
suffering from tuberculosis and leprosy and 0.5% to
13% of patients with ankylosing spondylitis,
rheumatoid arthritis, and Crohn’s disease.3
CASE ILLUSTRATION
A 30-years-old male, with diarrhea since 4 months
ago, was admitted to Cipto Mangunkusumo hospital
at November 2nd 2006. The patient had chronic
watery, non-bloody diarrhea about 5-6 times a day,
the frequency increased when he got more meals.
He had periumbilical cramps, nausea and vomiting, but
no fever. The patient had also anorexia, malaise, weight
loss of 20 kg in 4 months He had no palpitation.
The patient had leprosy at six years ago, was admitted
to Sitanala hospital and had been treated. He got
remission nine months ago. Since last year, he got
tumor in his neck, painless, and there was no
dysphagia. He smoked sometimes. There was no
history of free sex or drug abuse (IVDU). He had no
history of jaundice.
On physical examination, he looked moderately ill,
compos mentis, blood pressure 100/70 mmHg, pulse
rate 88 times/minute, respiratory rate 24 times/minute,
body temperature  36.5°C, nutritional status: worse,
conjunctivas were  pale and scleras were not icteric,
there were no oral thrush, thyroid gland palpable,
diffuse, painless, heart and lung were normal,
the abdomen was flat, supel, tenderness on abdomen,
the liver and spleen were not palpable. There were no
extremities oedema.
Laboratory examination showed Hb 7.5 g/dL, white
blood cells count 5,600/µL, platelet count 217,000/µL,
ureum 38 mg/dL, creatinine 1.1 mg/dL, AST 12 µ/L,
ALT 16 µ/L,  sodium 136 meq/L, potassium
1.8 meq/L, chloride 106 meq/L. Blood gas
examination revealed pH 7.36, pCO2 20.40 mmHg,
pO2 127.90 mmHg, HCO3 11.60 mmol/L,
O2 saturation 98.50%, and the electrolytes after
correction with KCl 50 meq in NaCl 500 ml/12 hours
were sodium 133 meq/L, potassium 3.03 meq/L,
chloride 102 meq/L, blood chemistry cholinesterase
1,402 U/L, total protein 4.1 g/dL, albumin level 2 g/dL,
globulin level 2.10 g/dL, Fe (SI) 4 µg/dL,
TIBC 115 µg/dL, transferrin saturation 12.17%,
ferritin 512.4 ng/ml,  TSHs 14.5 ì IU/mL, free T4
0.530 ng/dL. From the stool examination showed
greenish, watery stool, there were no blood, many white
blood cells, red blood cells 5-6, yeast cell positive.
Electrocardiogram showed sinus rhytm, QRS rate
100 times/minute, normoaxis, no ST changes, T inverted
in lead II, III, aVF, and poor R in lead V3-V4.
The chest X-ray showed no infiltrate and normal
figure.
From the preliminary data, the problem were chronic
diarrhea with low food intake, anemia microcytic
hypocrome, electrolyte imbalance, history of leprosy,
diffuse thyroid enlargement, and inferior coronary
arterial disease.
The initial treatments for this pasient were
rehydration with parenteral fluid normal saline infusion
500 ml/6 hours, high calory and high protein diet of
1,700 kkal, ranitidin 1 ampule twice daily, intravenous
ceftriaxone 1 g twice daily, New Diatab 2 tablets three
times daily, packed red cells transfusion untill
the haemoglobine level reach 10 g/dL, corrected
the potassium level with potassium chloride 50 mEq
in normal saline of 500 ml/12 hours, and gave
potassium suplementation tablet KSR  twice daily.
The patient was also given the tablet Ascardia 80 mg
once daily and oxygen therapy  3 liter/minute with
nasal canule.
After a couple of days, the evaluation from this
patient’s electrocardiogram showed sinus rhytm, QRS
rate 80 times/minute, normoaxis, there were no ST and
T changes, no LVH and RVH. It showed normal
pattern in his electrocardiogram. The pattern of
inferior coronary arterial disease on the first
electrocardiogram might be due to hypoxemia in this
patient.
The colonoscopy examination indicated internal
hemorrhoid grade II, pancolitis, ileitis, and the result
from histopathological examination showed chronic
destructive ileocolitis with 40-70% amyloidosis of
mucosa. The screening for HIV was examined and
the result showed non reactive. The CD 4 count was
749 (44%).
The abdominal ultrasonography showed chronic
cholecystitis, multiple cholelithiasis and minimally
ascites. The esophagogastroduodenoscopy indicated
candida esophagitis, erosive pangastritis grade V,
pyloring gapping, erosive duodenitis, bile reflux
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gastritis and esophagitis, and the result from histo-
pathological examination showed amyloidosis on
gastric mucosa. The immunofixation electrophoresis
was negative for monoclonal light chains, and
the serum protein electrophoresis showed normal
pattern.
During hospitalization, the patient’s condition was
not stable. He was treated every day with partial
parenteral nutrition and all antidiarrheal drugs, but it
was not successful to terminate diarrhea. The patient
had severe protein losing enteropathy and sustained
watery diarrhea. The patient had been monitored for
the possible infectious complications to the intractable
diarrhea. Some examinations of his stool showed
microsporidia and also yeast cells.
Then, the problems in this patient were gastro-
intestinal amyloidosis with intractable diarrhea,
malnutrition with hypoalbuminemia and electrolyte
imbalance, hypothyroidism with diffuse thyroid
enlargement as the clinical appearance, and also
pancytopenia during hospitalization.
It had been evaluated that high calory and high
protein nutrition was not suitable for this patient
because gastrointestinal amyloidosis gave symptoms
such as malabsorption, chronic dismotility and protein-
losing enteropathy. It had been tried to give simple
formation of nutrition for this patient and also parenteral
nutrition such as Triofusin 500, KaEN 3B, amino acid
infusion, and multivitamin. The supportive therapies
were also given to this patient such as antidiarrheal
drugs attapulgite (New Diatab®), loperamide
hydrochloride (Imodium®), metoclopropamide injection,
pancreatin 50 mg, papain 10 mg, ox bile 50 mg,
curcuma rhizoma 35 mg and liver extract 50 mg with
vitamin and minerals in one tablet (Vitazym®), Smecta®
1 sachet three times daily, lactobacillus (Lacbon®),
Oralyte® sachets, mesalazine (Salofalk®) 500 mg,
sucralfate C1 three times daily, L-thyroxine Na
(Thyrax®) 1/2 tablet twice daily, potassium
suplementation KSR 1 tablet twice daily, codein 20 mg
three times daily, albendazole  400 mg twice daily to
treat the secondary infection.
This patient had been consulted to the consultant of
gastroenterology division for the further treatment.
Finally, the prognose of this patient was not good, and
the aim of the treatment was just palliative treatment
because there were still limited researches about
the treatment of amyloidosis. It had been considered
to give steroid to this patient, but the patient had been
complicated by secondary fungal infections to his
 gastrointestinal tract.
It had been planned to give intravenous
metilprednisolone 62.5 mg twice daily to this patient
but it was considered to treat fungal infection first as
the secondary infection before giving the steroid.
The evaluation for chronic infection had been
established. C-reactive protein was examined and it
showed high value on the first laboratory result, it was
30.4 mg/L. This value increased higher on the next
evaluation, it was 161.3 mg/L. This patient had been
consulted to dermatology department to asses
the possibility of active chronic leprosy infection.
The assesment from his clinical appearance showed
n fiinactive infection and it was concluded that this
patient had recovered from leprosy. Skin biopsy had
also been planned in this patient to ensure whether the
infection had been inactive. But unfortunately, it had
been cancelled due to his severe condition.
During the hospitalization, this patient got
hypotension, his body weight lost about 1-2 kg every
week though his calories had been added through
enteral and parenteral nutrition. We had also tried to
correct hypoalbuminemia, electrolite imbalance, and
anemia. We had frequently given serum albumin
infusion, potassium chloride infusion, and packed red
cellstransfusion.
The last laboratorium test indicated pancytopenia
and also bilirubin level increased in this patient.
At the end of hospitalization, it became more difficult
to treat the problem of weight loss and electrolyte
imbalance. It had been considered to use central venous
access as parenteral nutritional access in this patient,
but it had been cancelled due to the problem
trombocytopenia.
The fungal infection in this patient became
a systemic infection due to immunocompromized
condition. We had tried to give antifungal medication
fluconazole 50 mg twice daily and antibiotic ceftriaxone
2 g once daily for non specific bacterial infection. But
these medications could not be optimized because of
financial problem.
Finally, we had difficulties to handle the systemic
infection problem in this patient. Beside, the general
condition of this patient became worse. The antibiotics
and also antifungal could not work optimally because
of malnutrition and hypoalbuminemia. This patient
finally died due to septicemia.
DISCUSSION
This case is a rare demonstration case of
amyloidosis with problem in management. This patient
manifested severe diarrhea unresponsive to
conventional treatment, hypoproteinemia, and protein
leakage. In this patient, biopsied tissues from the
upper and lower gastrointestinal tract showed
extensive deposition of amyloid. Amyloidosis is a unique
metabolic storage disease that results from deposition
of insoluble fibrillar proteins or aberrantly folded and
assembled protein fragments in a variety of tissues.
Classifications have grown from the simple notion of
Volume 9, Number 1, April  2008 27
Intractable Diarrhea Due to Secondary Gastrointestinal Amyloidosis in a Patient with History of Leprosy
primary and secondary amyloidosis, based on the broad
concepts of association with myeloma (primary) or
chronic illnesses (secondary), or concepts of
“systemic” or “localized” to current designations that
reflect the precursor protein. Treatment considerations
and prognosis depend on such identification.3
The presence of disease in more than one organ
system should increase the index of suspicion of
a systemic amyloidosis as the unifying diagnosis.
The pathological diagnosis of amyloidosis is established
by the identification of fibrillar tissue deposits.
We suspected this patient had a systemic amyloidosis
though only gastrointestinal tract had been biopsied to
establish the diagnosis amyloidosis. We suspected other
organs also clinically affected such as thyroid gland,
adrenal gland because there were some clinical
symptoms such as hypothyroidism, hypotension
(the blood pressure of this patient always around
80/50 mmHg), hyponatremia, hypokalemia, weakness,
anorexia, nausea, and vomiting. However, these
organs had not been biopsied due to some
considerations such as social condition and comfort for
the patient.
Systemic amyloidosis is generally progressive and
fatal; however, the natural history remains poorly
understood, partly due to the lack of clinical
recognition until the process is advanced. Amyloidosis
is not restricted to any age or gender group. Clinical
presentation depends on the distribution and the amount
of amyloid deposited, but symptoms may be protean
and generally, nonspecific. Well-known signs and
symptoms of systemic involvement include
macroglossia, nephrotic syndrome, renal failure,
carpal tunnel syndrome, sensory motor or autonomic
neuropathy, cardiac failure or arrhythmia, hepato-
splenomegaly, diarrhea, malabsorption, ulcerations,
lymphadenopathy, clotting factor deficiencies, capillary
fragility, and abnormalities of platelet aggregation.3
AL amyloidosis should be ruled in or out promptly
because it is the most common type of systemic
amyloidosis, can progress rapidly, and has a poor
prognosis if untreated.5 Since AL amyloidosis is
the most common type, a search for clonal plasma-cell
dyscrasia is the first step. Most commonly, AL
(primary) amyloidosis occurs in the setting of plasma
cell or B cell dyscrasias or monoclonal gammopathies;
amyloidosis may proceed clinically overt multiple
myeloma. In up to 15% of cases, no apparent
underlying cause is found. Involvement of
the gastrointestinal tract in AL amyloidosis (7%) may
cause life-threatening hemorrhage. The prognosis of
AL amyloidosis is poor: 12 to 15 months or less if
associated with multiple myeloma, liver involvement
(9%) does not impact this low survival rate.3
The presence of a monoclonal serum protein alone
is not diagnostic of amyloidosis; however, when it is
present in a patient with biopsy-proven amyloidosis,
the AL type should be suspected.5 Monoclonal
immunoglobulins or light chains are detected in 90% of
patients with AL amyloidosis by means of
immunofixation electrophoresis of serum or urine
a more sensitive technique than simple protein
electrophoresis.3 The immunofixation electrophoresis
in this patient was negative for monoclonal
gammopathy. This evidence guided us to other types
of  amyloidosis beside AL.
If there is no evidence of a plasma-cell dyscrasia,
consideration should be given to another form of
amyloidosis. Although a family history of amyloidosis
or unexplained progressive neuropathy strongly
suggests familial ATTR amyloidosis, a variant
transthyretin should be sought in all patients who do
not have a plasma-cell dyscrasia. Transthyretin can be
identified by isoelectric focusing of the serum, which
will separate variant and wild type transthyretin.
The finding of a variant transthyretin should prompt
specific genetic testing to identify the site of
the mutation. It is important to verify that the patient
has a plasma-cell dyscrasia before aggressive
treatment is undertaken. If none can be detected,
however, AL amyloidosis may still be present and should
be suspected if the patient has macroglossia with
the involvement of other, typical organ systems and no
variant transthyretin in the serum.3,5,6  The pattern of
serum electrophoresis in this patient was normal.
AA (secondary) amyloidosis was strongly suspected
in this patient because he had the underlying infectious
condition, leprosy. AA (secondary) amyloidosis occurs
in the setting of chronic inflammatory or infectious
conditions; the most common of the former are
rheumatoid arthritis, juvenile rheumatoid arthritis, and
ankylosing spondylitis. Malaria, leprosy, and
tuberculosis are chronic infections that may be
associated with AA amyloidosis. AA amyloidosis may
also occur in association with Hodgkin’s disease, and
gastrointestinal (GI) or genitourinary (GU)
malignancies. The precursor proteins include liver-
derived acute phase reactant serum amyloid A (SAA)
lipoproteins. The prognosis of AA amyloidosis is
reported as 50% 5-year survival and 25% 15-year
survival; however, hepatic involvement in AA
amyloidosis is a late manifestation and in contrast with
AL amyloidosis is associated with a significantly
reduced survival rate.3,5 Unfortunately,
the identification of an AA amyloid deposit by
immunohistochemical staining with permanganate
sensitivity had non been done yet.
The prevalence of clinically apparent gastro-
intestinal involvement varies considerably, depending
on the type of amyloidosis. Gastrointestinal disease was
reported in up to 60% of patients with AA amyloidosis
secondary to rheumatoid arthritis. By contrast,
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gastrointestinal manifestations appear to be less
common in patients with AL amyloidosis. In a large
series of 769 patients with primary amyloidosis, only
8% had biopsy proven gastrointestinal involvement,
leading to symptoms in only 8 patients. Among these
symptoms, bleeding events were less prevalent
compared with other symptoms, such as
malabsorption, chronic dysmotility, or protein-losing
enteropathy. However, cases of severe and sometimes
lifethreatening bleeding events were reported not only
in patients with AA amyloidosis, but also in those with
AL amyloidosis, which may reflect unique patho-
physiological mechanisms.7
Furthermore, some cases showed possible causes
of induction of intractable diarrhea (operation,
infection or extraarticular manifestation). SAA, which
is the precursor of amyloid a protein, is known to be
synthesized in the liver and the process is stimulated
by macrophage derived cytokines such as interleukin
1, interleukin 6 or tumor necrosis factor, thus it rapidly
increases in blood at the time of acute inflammation in
parallel with acute phase proteins such as C reactive
protein. It is considered that high activity of arthritis,
infection; surgery and extraarticular manifestation of
RA induce a rapid increase of SAA and promote
the deposit of amyloid, which might contribute to
the onset of intractable diarrhea. With regard to renal
function, most patients had normal values of creatine.
Even in one patient who had increased concentrations
of creatinine at the time of the onset of intractable
diarrhea, those values returned to normal after
recovery from dehydration. It is generally assumed that
intractable diarrhea tends to manifest earlier than
renal dysfunction. In fact, in 15 cases (63%)
the opportunity to diagnose amyloidosis was the onset
of intractable diarrhea. Other opportunities to diagnose
amyloidosis were at the time of the endoscopic upper
gastrointestinal screening of amyloidosis and the onset
of other digestive symptoms. There was no case of
nephropathy such as renal failure or massive proteinuria
before the onset of intractable diarrhea. With regard
to clinical symptoms, abdominal pain, nausea and
vomiting were seen in almost all cases. Abdominal
distension with decreased bowel sounds on
auscultation was recognised in about two thirds of
the cases, which suggested the impaired peristalsis
resulted from amyloid deposit, a characteristic finding
of gastrointestinal amyloidosis. During the course of
diarrhea, all cases showed severe hypoproteinaemia
and hypoalbuminaemia. These results suggested
malabsorption or protein loss. Moreover, highly
increased values of C reactive protein during the
clinical course were pathognomonic of intractable
diarrhea. The increased value of C reactive protein is
assumed to be caused by severe intestinal
inflammation. In addition, we speculate that ischemia
of the intestinal mucosa and gastrointestinal infection
is the causes of intestinal inflammation. With regard to
infection, no causative bacteria such as Shigella,
Salmonella, Vibrio or enteropathogenic Escherichia
coli were detected in faces culture. Thus, it cannot be
denied that change or increase of some kind of
intestinal bacterial flora or viral infection may have
triggered the gastrointestinal inflammation. From these
clinical symptoms and abnormal laboratory data,
the impaired motility and inflammation of the intestine
are assumed to be important pathogenic factors of
intractable diarrhea. It is probable that amyloid
infiltration of the intestinal smooth muscle or
gastrointestinal neuropathy with amyloid involvement
of the autonomic nerves caused impaired motility of
the intestines.8,9
At present, the most effective approach to
the treatment of the systemic amyloidoses involves
shutting down or substantially reducing the synthesis
of the amyloid precursor. In reactive amyloidosis (AA),
control of the underlying inflammatory disorders can
result in regression of the disease.10
Supportive treatment for all forms of amyloidosis is
an important adjunct to major antiamyloidogenic
treatment. It can enhance the effectiveness of major
treatments and improve the quality of life for all
patients. Autonomic neuropathy may be clinically
manifested as severe orthostatic hypotension or
gastrointestinal dysfunction. Metoclopropamide may be
helpful to increase gastric motility. Intestinal motility
dysfunction may cause constipation, diarrhea, or
alternating symptoms of both. Diarrhea may respond
to limiting fat in the diet (< 40 g), medium-chain
triglyceride oil supplements, medications to decrease
bowel motility (loperamide), or to increase bowel
contents psyllium hydrophilic muciloid. Some patients
with gastrointestinal dysfunction may benefit from oral
nutritional supplementation, but some may require
parenteral nutritional support to avoid malnutrition.5
We had tried to give optimal supportive treatment to
this patient. We tried to give simple form of oral
nutritional supplementation and partial parenteral
nutrition. Finally, we considered giving total parenteral
nutrition through central venous access, but
unfortunately the condition of this patient became worse
and it was impossible to do more invasive action.
At present, the major therapeutic strategy is
treatment of the primary inflammatory disease in
order to reduce the circulating levels of the amyloid
precursor protein SAA. Intensive treatment that
lowers SAA levels to less than 10 mg/L may halt
disease progression and induce a slow progressive
recovery of renal function. Accounts exist of
the disappearance of the amyloid deposits associated
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with tuberculosis or chronically infected burns with
appropriate treatment of the infection. Similarly, case
reports exist of the disappearance of amyloid
deposition associated with chronic inflammatory bowel
disease after resection of the affected section of
bowel.10
The following are new approaches to the treatment
of AA amyloidosis that are currently undergoing
clinical trials:11
· A low–molecular-weight sulfonated molecule has
been developed that interferes with fibril
formation and deposition of amyloid by inhibiting
interaction of SAA with glycosaminoglycans.
In experimentally induced murine AA amyloidosis,
this drug (NC-503) has been shown to reduce
the amount of amyloid deposits.12
· Dimerization of human SAP molecules in vivo with
a palindromic compound (CPHPC) triggers very
rapid clearance of the complexed protein by
the liver, depleting SAP from the circulation within
a few hours of drug administration.
· Anti–IL-6R therapy appears promising for
the treatment of AA amyloidosis.
· A case report exists of severe protein-losing
enteropathy with intractable diarrhea due to
systemic AA successfully treated with
corticosteroids and octreotide.13
· A single patient with AA amyloidosis secondary to
Hodgkin disease was administered 4'-iodo-
4’deoxydoxorubicin as antitumor therapy, this
patient has been reported to show a reduction in
proteinuria and the liver amyloid burden on
biopsy. The response was not complete and
the resolution on liver biopsy may have been
the result of sampling differentially infiltrated
portions of tissue; nonetheless, the result is
potentially exciting.
· A more experimentally and theoretically based
approach uses the observation that anionic
sulphonates interfere with the deposition of AA
fibrils in a murine model of inflammatory
amyloidosis. One of these compounds is in clinical
trials, the results of which should be available over
the next 2 years. Little or no toxicity was shown in
the preclinical testing.
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